This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abreu, T.
Right arrow Articles by Lambert, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abreu, T.
Right arrow Articles by Lambert, J. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2000, p. 1375-1376, Vol. 44, No. 5
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Bioavailability of Once- and Twice-Daily Regimens of Didanosine in Human Immunodeficiency Virus-Infected Children

Thalita Abreu,1 Karen Plaisance,2,* Vivian Rexroad,3 Susie Nogueira,1 Ricardo Hugo Oliveira,1 Lucia A. Evangelista,1 Rosana Rangel,1 Irene S. Silva,1 Cathy Knupp,4 and John S. Lambert5

Federal University of Rio de Janeiro, Rio de Janeiro, Brazil1; Institute of Human Virology5 and School of Pharmacy,2 University of Maryland, and Johns Hopkins Medical Institutions,3 Baltimore, Maryland; and Bristol-Myers-Squibb, Princeton, New Jersey4

Received 26 May 1999/Returned for modification 29 November 1999/Accepted 7 February 2000

The bioavailability of didanosine at 180 mg/m2 once daily was compared to that at 90 mg/m2 twice daily in 24 children with advanced human immunodeficiency virus infection. Children were studied at steady state using optimal sampling and prior pharmacokinetic parameter estimates. Relative bioavailability was 0.95 ± 0.49, supporting the potential clinical adequacy of once-daily dosing.

* Corresponding author. Mailing address: University of Maryland School of Pharmacy, 100 Penn St., Baltimore, MD 21201. Phone: (410) 706-4335. Fax: (410) 706-6580. E-mail: kplaisan{at}rx.umaryland.edu.

Antimicrobial Agents and Chemotherapy, May 2000, p. 1375-1376, Vol. 44, No. 5
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Hirt, D., Bardin, C., Diagbouga, S., Nacro, B., Hien, H., Zoure, E., Rouet, F., Ouiminga, A., Urien, S., Foulongne, V., Van De Perre, P., Treluyer, J.-M., Msellati, P. (2009). Didanosine Population Pharmacokinetics in West African Human Immunodeficiency Virus-Infected Children Administered Once-Daily Tablets in Relation to Efficacy after One Year of Treatment. Antimicrob. Agents Chemother. 53: 4399-4406 [Abstract] [Full Text]  
  • Rongkavilit, C., Thaithumyanon, P., Chuenyam, T., Damle, B. D., Limpongsanurak, S., Boonrod, C., Srigritsanapol, A., Hassink, E. A. M., Hoetelmans, R. M. W., Cooper, D. A., Lange, J. M. A., Ruxrungtham, K., Phanuphak, P. (2001). Pharmacokinetics of Stavudine and Didanosine Coadministered with Nelfinavir in Human Immunodeficiency Virus-Exposed Neonates. Antimicrob. Agents Chemother. 45: 3585-3590 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»